Greg Luerman
Vice President, Research & Partnerships Curi Bio
Seminars
Wednesday 9th December 2026
De-Risking Muscle-Sparing Obesity Programs with Human Engineered Muscle Tissues: Industry Adoption & the Regulatory Shift
2:30 pm
- Measuring muscle quality – force, fatigue, glucose uptake and atrophy – directly in primary human (engineered) tissues
- Highlighting recent industry-authored publications applying these models to obesity and metabolic biology
- Tracking how FDA and global regulators are actively incentivizing NAMs, from the animal-testing phase-down roadmaps to formal qualification pathways for human-relevant models
